Navigation Links
Todd Rider Joins Draper to Continue Antiviral Therapeutics Development

Cambridge, MA (PRWEB) January 08, 2014

Todd Rider has joined Draper Laboratory to continue his work on treatments that are effective against a wide array of pathogens, rather than specific threats.

Rider received his Ph.D. from MIT in 1995 and served as a senior staff scientist at MIT Lincoln Laboratory until October 2013. While at Lincoln Laboratory, Rider began development of a broad-spectrum antiviral therapeutic drug called DRACO, which TIME Magazine hailed as one of the top inventions of the year 2011, and the White House described as “visionary” in its 2012 National Biotechnology Blueprint.

Upon administration to an animal or hopefully someday a person, Rider’s DRACO drug rapidly identifies virus-infected cells and eliminates them while leaving healthy cells untouched, thus eliminating the infection. DRACO, which stands for Double-stranded RNA Activated Caspase Oligomerizer, has proven effective and nontoxic in mice and in 11 different human and animal cell types against 15 different viruses, ranging from the common cold to dengue hemorrhagic fever.

Rider is expanding his DRACO research at Draper and is testing against strains of various other viruses in cells and animals; the team looks forward to larger scale animal trials and clinical human trials within a decade or less. DRACO is part of Rider’s PANACEA project, a family of broad-spectrum therapeutics that he invented.

Rider holds a joint appointment with MIT’s Edgerton Center, where he is also working to develop innovative programs to improve K-12 science education, drawing on his extensive previous experience creating and running educational outreach programs at Lincoln Laboratory.

Draper Laboratory

Draper Laboratory, which celebrates 80 years of service to the nation in 2013, is a not-for-profit, engineering research and development organization dedicated to solving critical national problems in national security, space systems, biomedical systems, and energy. Core capabilities include guidance, navigation and control, miniature low power systems, highly reliable complex systems, information and decision systems, autonomous systems, biomedical and chemical systems, and secure networks and communications.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. "Just Label It" condemns dangerous riders snuck into the Farm Bill by chemical companies working to keep Americans in the dark about their food
2. Jesper Bramming, former A.P. Moller Executive, Joins the CMC Biologics Executive Management Team as Chief Financial Officer
3. Dr. Daniel Von Hoff Joins Lixte Biotechnologys Scientific Advisory Board
4. Bioentrepreneurship Leader Joins UM Ventures Team
5. Anthony A. Charity Joins Tunnell Consulting
6. CHI Joins More Than 30 State Life Sciences Associations in Urging Budget Conferees to Fix FDA User Fee Sequester
7. Craig Peloquin Joins Glissandra Skin Care as VP of Sales and Marketing
8. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
9. Dr. Ungerleider Joins Forces with Childhelp
10. ReachMD Radio Joins Clear Channel’s iHeartRadio
11. Soltex Consulting Joins Medidata Partner Program to Better Optimize Clinical Processes
Post Your Comments:
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
Breaking Biology Technology:
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/12/2015)...   Growing need for low-cost, easy to ... paving the way for use of biochemical sensors ... in clinical, agricultural, environmental, food and defense applications. ... medical applications, however, their adoption is increasing in ... emphasis on improving product quality and growing need ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
Breaking Biology News(10 mins):